Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.Frontiers in pharmacology · 2022
   Pooled it
2. Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review.Scandinavian journal of immunology · 2021
   Pooled it
3. Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical Trial.Clinical and translational science · 2026
   Trial
4. Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial.Medicine · 2022
   Trial
5. Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.British journal of haematology · 2022
   Trial
6. Circulating Interleukin-6 and CD16 positive monocytes increase following angioplasty of an arteriovenous fistula.Scientific reports · 2022
   Trial
7. Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients.PloS one · 2022
   Trial
8. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
   Trial
9. Dipeptidylpeptidase 4 inhibition attenuates gestational pathologies via immune homeostasis restoration in the pulmonary-uterine axis.Nature communications · 2026
   Article
10. Serum Cytokine Profiling Differentiates Underlying Diseases in Cytokine Storm Syndrome.Arthritis & rheumatology (Hoboken, N.J.) · 2026
    Article
11. Comparison of Antipsychotics in the Treatment of COVID-19-Induced First-Episode Psychosis: A Review of Case Studies.Cureus · 2026
    Review
12. Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies.Viruses · 2024
    Review
13. N-glycosylation of the SARS-CoV-2 spike protein at Asn331 and Asn343 is involved in spike-ACE2 binding, virus entry, and regulation of IL-6.Microbiology and immunology · 2024
    Article
14. Thyroid tuberculosis and cold abscess after infection with COVID-19: A case report.Heliyon · 2024
    Article
15. The disruptive role of LRG1 on the vasculature and perivascular microenvironment.Frontiers in cardiovascular medicine · 2024
    Review
16. Development of a prediction nomogram for IgG levels among asymptomatic or mild patients with COVID-19.Frontiers in cellular and infection microbiology · 2024
    Article
17. The immune-adjunctive potential of recombinant LAB vector expressing murine IFNλ3 (MuIFNλ3) against Type A Influenza Virus (IAV) infection.Gut pathogens · 2023
    Article
18. Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response.Life (Basel, Switzerland) · 2023
    Review
19. Quantitative multiorgan proteomics of fatal COVID-19 uncovers tissue-specific effects beyond inflammation.EMBO molecular medicine · 2023
    Article
20. The influence of SARS-CoV-2 infection on expression of drug-metabolizing enzymes and transporters in a hACE2 murine model.Pharmacology research & perspectives · 2023
    Article

27 more citing papers are in PubMed but not listed here.

Corrections and comments

• Comment on
  Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.2021
• Comment on
  Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.2021

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as